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Background and Objectives: Recurrence after partial liver resection for hepatocel-
lular carcinoma (HCC) is a major cause of death from this disease. To identify risk
factors for early death from recurrence after liver resection for HCC.
Methods: All 547 patients in this study had greater than 1 year of follow-up after
complete resection of HCC (1980–1999) at one of the four hepatobiliary centers in
Japan, France, and the United States. Patients who died of recurrence 1 year post-
resection and all of those alive at least 1 year were compared. Survival and clinico-
pathological factors associated with death from recurrence within 1 year of resection
were analyzed.
Results: Overall postoperative mortality rate was 5%. In the first postoperative year,
123 (22%) patients died. Of these, 53 (43%) died of recurrence, 30 (24%) of post-
operative complications, and 40 (33%) of liver failure/hemorrhage. On multivariate
analysis, tumor size greater than 5 cm (P< 0.02; odds ratio, 3.0), multiple tumors
(P< 0.01; odds ratio, 3.3), and greater than 5 mitoses per 10 high-power fields
(P< 0.03; odds ratio, 3) were associated with increased risk of early death due to
recurrence.
Conclusions: These findings enable identification of patients with HCC who are at
high risk for early death due to recurrence following potentially curative resection who
might be candidates for adjuvant therapy trials.
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INTRODUCTION
Liver resection is the only curative treatment for
hepatocellular carcinoma (HCC). Over the past 2 de-
cades, death in the early postoperative period has been a
major pitfall of this procedure [1]. However, identifica-
tion of preoperative risk factors for postoperative liver
failure in patients with cirrhosis [2–4] and improvements
in surgical technique [5–7] have made partial liver resec-
tion safer and have prompted re-evaluation of overall and
disease-free survival rates after resectional therapy for
HCC.
Although patterns of recurrence after potentially
curative resection for HCC have been documented in
detail in several studies, only a few reports have
This study was carried out by the International Cooperative Study Group on
Hepatocellular Carcinoma at various centers mentioned in the affiliations.
*Correspondence to: Dr. Jacques Belghiti, MD, Service de Chirurgie,
Hoˆpital Beaujon 100, Boulevard du Ge´ne´ral Leclerc, 92 118 Clichy Cedex,
France. Fax number: (33).1.40.87.09 26.
E-mail: j.bel@bjn.ap-hop-paris.fr
Accepted 2 June 2003
DOI 10.1002/jso.10284
Published online in Wiley InterScience (www.interscience.wiley.com).
 2003 Wiley-Liss, Inc.
examined early recurrence (i.e., within the first year).
Previously reported risk factors for early recurrence
reflect tumor characteristics—such as high preoperative
alpha-fetoprotein level, intrahepatic metastasis [8], large
tumor size [9], presence of venous invasion [10,11],
tumor rupture [11]—and liver function characteristics,
such as high serum alanine transferase level [12]. To our
knowledge, the risk factors for death due to recurrence
within the first year after liver resection for HCC have not
been studied. Because as many as 28% of patients can
survive 3 years without treatment [13], it can be argued
that the value of resection is questionable for some pa-
tients who are at high risk of death due to recurrence less
than 1 year after resection. The need for better patient
selection criteria for resection is apparent.
The aim of this study was to identify risk factors for
early death (1 year) due to recurrence after partial
liver resection for HCC using a multi-institutional data-
base of liver resections performed at four hepatobiliary
centers.
MATERIALS AND METHODS
Patient Selection
A multi-institutional database was developed from the
prospective databases at The University of Texas M. D.
Anderson Cancer Center (Houston, Texas), Mayo Clinic
(Rochester, Minnesota), Kyoto University Graduate
School of Medicine (Kyoto, Japan), and Hoˆpital Beaujon
(Paris, France). All patients underwent partial hepatic
resection for HCC with curative intent between 1980 and
1999. Complete histopathologic review of the slides and
clinical reports was performed on site by three of the
authors (J.N.V., D.M.N., and G.Y.L.).
Mortality rate during the postoperative period, which
includes all deaths within 31 days after surgery, was 5%
(30/591). Overall 5- and 10-year survival rates for the
entire cohort were 39 and 17%, respectively. The median
follow-up time for the entire cohort was 33 31 months
(range, 0–206 months).
After exclusion of 28 patients who died of unknown
causes and 16 patients with follow-up of less than 1 year,
547 patients were included in this study. Patients were
divided into two groups: those who died of recurrence
within 1 year after liver resection and those who survived
at least 1 year after liver resection, whatever their status at
last follow-up (dead with or without recurrence, alive
with or without recurrence).
Death due to recurrence of HCC was strictly defined
when evidence of recurrence was documented and no
other cause of death was found after analysis of the
clinical data. Recurrence was confirmed according to the
usual practices for clinical research at each institution.
Criteria for diagnosis of recurrence included a rising
serum alpha-fetoprotein concentration compared with the
post-resection baseline level, and imaging or postmortem
evidence of intrahepatic or extrahepatic recurrence as
the proximate cause of death. Radiological criteria for
the diagnosis of HCC were as follows: (a) one or more
hypoechoic, hyperechoic, or mixed nodules on ultra-
sonography in association with one or more hypervas-
cular nodules with enhancement in the arterial phase
on computed tomography (CT) and/or (b) one or more
hypervascular nodules on magnetic resonance imaging
(MRI) with gadolinium infusion. When findings on CT
scan or MRI were inconclusive or discordant, hepatic
angiography with infusion of iodized oil (Lipiodol, Ultra-
Fluide, Laboratoires Guerbet, Aulnay-sous-Bois, France)
was performed. Biopsy was not required to define
recurrence.
Criteria Analyzed
Deaths due to recurrence of HCC were plotted as a
function of time after resection. The following criteria
were studied in all patients: (a) age, sex, and ethnic
origin; (b) Child–Pugh class, based on a scoring scheme
described elsewhere [1,14]; (c) serum alpha-fetoprotein
level; (d) hepatitis B serology (serologic presence of any
hepatitis B antigen or antibody; data concerning hepatitis
C status were available for only a minority of patients);
(e) tumor characteristics, including number of tumors
(single or multiple), intrahepatic distribution of tumor(s)
(unilobar or bilobar), tumor size (based on the largest
dimension of the tumor specimen), histopathologic type
(microtrabecular or macrotrabecular, acinar, diffuse),
tumor grade (according to the scheme outlined by
Edmondson and Steiner [15] and based on the area of
highest grade), degree of necrosis, presence or absence of
a peritumoral fibrous capsule (and capsular invasion),
number of mitoses per 10 high-power fields (less than or
more than 5—with the cutoff value of 5 representing the
median value), nuclear polymorphism (graded as mild,
moderate, or marked), minor vascular invasion (defined
as either gross or histological involvement of the lobar or
segmental branches of the portal or hepatic vein), and
major vascular invasion (defined as gross invasion of the
right or left main branches of the portal or hepatic vein)
[16]; (f) type of resection (hepatic lobectomy and greater
versus less than a formal lobectomy—i.e., wedge resec-
tion or segmentectomy); (g) surgical margin (defined as
the closest margin on paraffin section and classified as
less than 10 vs. 10 mm or greater); and (h) characteristics
of the host liver: hepatitis activity grade (0–5 and 6–12
vs. 13–18) and extent of fibrosis/cirrhosis (fibrosis stage:
0–2 [mild], 3–4 [moderate], or 5–6 [severe/cirrhosis])
based on the modified grading and staging scheme for
chronic hepatitis proposed by Ishak et al. [17].
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Statistical Analysis
Quantitative data were expressed as means SD.
Groups were compared by univariate analysis using the
chi-square test or Students t-test as appropriate, and by
multivariate analysis using logistic regression analysis
with backward and forward step selection (performed on
significant variables in univariate analysis).
RESULTS
Causes of Death Within 1 Year
One hundred twenty-three (22%) patients died in the
first year after surgery. Of these, 53 (43%) died of recur-
rence, 40 (33%) of liver failure/hemorrhage, and 30 (24%)
of postoperative complications. No patient who died of
a postoperative complication was found to have recur-
rence. Figure 1 reveals that deaths from recurrence or
liver failure/hemorrhage occured throughout the first year
post-resection.
Of the patients who died of recurrence within 1 year
after resection, 42 were men and 11 women, and the
mean age was 59 15 years (range, 18–82 years). The
control group of patients who survived greater than 1 year
included 282 men and 142 women, and the mean age was
59 13 years (range, 15–96 years). The mean follow-up
interval of these patients was 55 32 months (range, 12–
206 months).
Analysis of the entire cohort of 547 patients demon-
strated that most deaths from recurrence occur within the
first year after potentially curative resection (Fig. 2).
Finally, precise pattern of recurrence data were available
for 29 of the 53 patients who died of recurrence: 4/29
recurred at a distant site only while 25 recurred in the
liver (23 in the liver only, 2 in the liver and at a distant
site).
Factors Predictive of Early Death
due to Disease Recurrence
Of the 21 variables assessed in the univariate analysis,
only 6 were associated with a significantly higher risk of
death within the first year after liver resection: tumor
size greater than 5 cm (76 vs. 42%, P¼ 0.004), multiple
tumors (51 vs. 30%, P¼ 0.03), presence of minor vasc-
ular invasion (68 vs. 42%, P¼ 0.005) or major vascular
invasion (30 vs. 13%, P¼ 0.01), more than 5 mitoses per
10 high-power fields (80 vs. 46%, P¼ 0.02), and hepatitis
grade less than 5 (85 vs. 58%, P¼ 0.04) though every
data point was not available for analysis in every patient
(Table I).
In multivariate analysis, only tumor size greater than
5 cm (P¼ 0.03), multiple tumors (P¼ 0.01), and more
than 5 mitoses per 10 high-power fields (P¼ 0.03) re-
mained associated with a significantly higher risk of
death within the first year after liver resection (Table II).
Eighteen (38%) of the 47 patients with all 3 risk factors
died in the first year after liver resection (sensitivity, 35%;
specificity, 93%; positive predictive value, 38%; negative
predictive value, 96%). Two (2%) of the 88 patients with
none of the risk factors died within first year. The sensi-
tivity, specificity, positive predictive value, and negative
predictive value for these predictive criteria are summar-
ized in Table III.
DISCUSSION
Early recurrence after liver resection is one of the most
important factors that impact the prognosis and quality of
life of patients with HCC. Results of this multicenter
study indicate that despite improvements in patient selec-
tion and operative technique, at least 10% of the patients
who undergo radical surgery for HCC die of recurrence
within the first year after resection. Recurrent disease
was the leading cause of death during the first year after
complete primary tumor resection. Only factors reflecting
tumor behavior—tumor size greater than 5 cm (76 vs.
42%), multiple tumors (51 vs. 30%), and presence of
more than 5 mitoses per 10 high-power fields (80 vs.
46%)—predicted increased risk of early death due to
recurrence.
Fig. 1. Deaths due to recurrent hepatocellular carcinoma (HCC) and
liver failure/hemorrhage within the first year after resection.
Fig. 2. Deaths due to recurrent HCC within the first 5 years after
resection. Deaths within 31 days after resection and deaths for which
the cause was unknown are not represented in this figure.
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Several series have indicated that the underlying liver
disease has a more important role in predicting long-term
survival after hepatic resection than tumor characteristics
[1,18,19]. There are two possible explanations for the
adverse effect of existing fibrosis or cirrhosis on long-
term survival. First, patients with advanced fibrosis or
cirrhosis are more likely to develop recurrence of the pri-
mary HCC and subsequently die of the disease. Second,
fibrosis and cirrhosis may represent a field of canceriza-
tion associated with development of a new metachronous
HCC after resection [20–22]. In the series presented here,
no factor reflecting the nature of the nontumorous host
liver was a reliable predictor of early death.
It is widely accepted that large tumor size, especially
tumor size greater than 5 cm, predicts a high risk of tumor
recurrence after resection [20–23]. Moreover, tumor size
TABLE I. Univariate Analysis of Possible Predictive Factors of Early Death due to Recurrence Following Resection of HCC
% Of patients or (mean SD)
P valueDeath 1 year due to recurrence Control group
Patient characteristics
Sex, % male 79 67 n.s.
Age (59 15) (59 13) n.s.
Country of origin, France/United States/Japan 21/30/49 31/41/28 n.s.
Childs classificationa, A/B/C 57/43/0 70/30/0 n.s.
Serum alpha-fetoprotein (ng/ml) 19,710 54,084 4,258 24,607 n.s.
Hepatitis B serology positivea 30 34 n.s.
Tumor characteristics
Tumor size, mm (81 39) (60 42) 0.004
Tumor number, single/multiple 49/51 70/30 0.03
Tumor location, uni/bilobar 83/17 91/10 n.s.
Histopathologic type
Micro/macrotrabecular 20/30 22/24 n.s.
Acinar/diffuse 22/28 13/41 n.s.
Tumor gradea
Well/moderately differentiated —/29 9/55 n.s.
Poorly/undifferentiated 71/— 32/4 n.s.
Degree of necrosis, 0%/<50%/50%/100% 33/52/8/7 46/38/9/7 n.s.
Fibrous capsule present 60 40 n.s.
Microvascular invasion present 68 42 0.005
Macrovascular invasion present 30 13 0.01
Nuclear polymorphism
Mild/moderate/marked 2/39/59 14/43/43 n.s.
>5 Mitoses per 10 high-power fields 80 46 0.02
Nontumorous liver characteristics
Hepatitis gradea, 0–12/13–18 85/15 58/42 0.04
Fibrosis gradea, 0–2 (mild)/3–4 (moderate)/5–6 (severe) 44/17/39 30/21/49 n.s.
Surgical factors
Resection type
Hepatic lobectomy or greater 40 56 n.s.
Wedge resection or segmentectomy 60 44 n.s.
Margina, <10 mm/10 mm 61/39 52/48 n.s.
SD, standard deviation; n.s., not statistically significant.
Patients who died within the first year after liver resection because of postoperative complications (n¼ 30) or liver failure/hemorrhage (n¼ 40)
were excluded from the analysis.
aEvery data point evaluated in this table was available for 98–100% of patients except preoperative Childs Classification (available in 70% of
early recurrence group and 77% of control group), AFP (77 and 84%, respectively), fibrous capsule (96 and 94%), hepatitis and fibrosis grade
(85–92% in each group), and margin size (79 and 83%).
TABLE II. Logistic Regression Analysis of Significant Predictive Factors of Early Death due to Recurrence Following Resection for HCC
From Univariate Analysis
Risk factor Wald chi square Odds ratio Standard error P value
More than 5 mitoses per 10 high-power fields 4.3 3.0 0.52 0.037
Tumor size greater than 5 cm 4.7 3.0 0.51 0.030
Multiple tumors 5.6 3.3 0.50 0.018
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greater than 5 cm is a recognized limitation to orthotopic
liver transplantation [24,25]. In the series of Bismuth
et al. [24], 3-year disease-free survival rate was 60% in
patients with tumor size less than 3 cm versus only 28%
in patients with tumor size greater than 5 cm (P< 0.05).
One of the mechanisms favoring the association of early
recurrence and death with larger tumor size may be a de
facto incomplete resection in spite of apparent margin-
negative resection. Indeed, Yoshida et al. [26] and Lai
et al. [27] have reported that in the case of large tumors, a
margin of 10 mm from the cut surface of HCC in the fresh
resected specimen is inadequate to achieve cure. Lai et al.
have also shown that when the tumor size is 4 cm or
greater, microsatellites may be found more than 90 mm
from the dominant nodule [27]. Consistent with these
pathological results, studies have shown an improvement
in survival rate when the width of the surgical margin is
greater than 1 cm [28,29]. However, multivariate analyses
in larger series have failed to show that wider resection
margins overcome traditional risk factors for recurrence
and shorter survival, such as the presence of venous
invasion or satellite lesions [30]. A higher incidence of
intrahepatic metastasis and portal venous invasion with
tumors larger than 5 cm [20,31] underscores the prog-
nostic significance of large tumor size.
Recent studies suggest that vascular invasion is a
strong predictor of outcome in patients with HCC after
resection [10,11,32] or orthotopic liver transplantation
[33] (number of mitoses was not considered in these
series). Although vascular invasion was a significant
predictor of early death by recurrence in this series, its
confidence interval failed to reach statistical significance
on multivariate analysis, likely because of confounding
by high levels of cell proliferation and sample size
limitations. Careful analysis of these and literature-based
data, which report degree of cell proliferation and sur-
vival, are revealing. Prior reports suggest that tumor size
and number of nodules are factors linked with recurrence
but not with death due to recurrence after resection, and
these studies have not examined the risk for death in the
first year after resection [29,30]. Tumor biologic factors
related to the growth and invasiveness of HCC may be
more relevant indicators of death due to recurrence after
resection. Indeed, we found that the proliferative activity
as measured by increased mitotic activity was a risk
factor for early death due to recurrence [30]. The level of
proliferating cell nuclear antigen, the expression of which
is related to DNA synthesis and cell replication, has been
reported to be associated with a higher incidence of
venous invasion and direct liver invasion, which in turn
may play an important role in survival [34,35]. Similarly,
Soini et al. [36] have shown that HCC with a high
proliferation index, and a low degree of apoptosis and
necrosis is associated with shortened survival. In aggre-
gate, these results suggest that the degree of cell proli-
feration should be added to the classic pathological
prognostic factors for HCC. Although the present study is
retrospective, and therefore every data point is not avail-
able for every patient, multivariate analysis confirms the
importance of multiple tumors, tumor size, and presence
of mitotic activity as statistically significant prognostic
factors (Tables II and III).
The identification of significant prognostic factors for
early death due to recurrence may not only improve
patient selection for resection of HCC but also enable
better selection of patients for postoperative adjuvant
therapy. Systemic chemotherapy and hormonal therapy
have failed to improve disease-free or overall survival
rates in HCC [11,37]. However, several other adjuvant
approaches have shown promise, including postoperative
transarterial chemoembolization [11,38], intra-arterial
iodine-131-labelled Lipiodol infused during transarterial
chemoembolization [39], or adoptive immunotherapy
[40].
CONCLUSIONS
We propose that the patients with a high risk of recur-
rence within the first year after primary tumor resection
for HCC—i.e., the patients with tumors larger than 5 cm,
TABLE III. Sensitivity, Specificity, Positive Predictive Value and Negative Predictive Value of Predictive Criteria of Early Death due to
Recurrence Following Resection for HCC
Criterion No. of patients Sensitivity (%) Specificity (%) PPV (%) NPV (%) Accuracy (%)
All three criteria present 47 35 93 38 92 86
Two criteria present
>5 cm and multiple tumors 78 40 86 27 92 82
>5 cm and >5 mitoses 115 28 94 61 81 78
Multiple tumors and >5 mitoses 86 26 92 42 84 80
One criterion present
>5 cm tumor 222 18 95 79 58 60
Multiple tumors 153 52 70 18 92 68
>5 mitoses 164 58 69 18 93 67
PPV, positive predictive value; NPV, negative predictive value; ‘‘>5 mitoses’’ indicates greater than 5 mitoses per 10 high-power fields.
40 Regimbeau et al.
multiple tumors, or more than 5 mitoses per 10 high-
power fields, and particularly those with 2 or 3 of these
risk factors—should be enrolled in adjuvant therapy trials.
Future studies are necessary to integrate tumor biology
into the current treatment algorithm to enable optimal
selection of patients for surgical and adjuvant therapies.
REFERENCES
1. Vauthey JN, Klimstra D, Franceschi D, et al.: Factors affecting
long-term outcome after hepatic resection for hepatocellular
carcinoma. Am J Surg 1995;169:28–35.
2. Noun R, Jagot P, Farges O, et al.: High preoperative serum alanine
transferase levels: Effect on the risk of liver resection in child
grade A cirrhotic patients. World J Surg 1997;21:390–394.
3. Farges O, Malassagne B, Flejou JF, et al.: Risk of major liver
resection in patients with underlying chronic liver disease: A
reappraisal. Ann Surg 1999;229:210–215.
4. Torzilli G, Makuuchi M, Inoue K, et al.: No-mortality liver
resection for hepatocellular carcinoma in cirrhotic and noncir-
rhotic patients: Is there a way? A prospective analysis of our
approach. Arch Surg 1999;134:984–992.
5. Fong Y, Sun RL, Jarnagin W, et al.: An analysis of 412 cases of
hepatocellular carcinoma at a Western center. Ann Surg 1999;
229:790–799.
6. Fan ST, Ng IO, Poon RT, et al.: Hepatectomy for hepatocellular
carcinoma: The surgeon’s role in long-term survival. Arch Surg
1999;134:1124–1130.
7. Imamura H, Shimada R, Kubota M, et al.: Preoperative portal vein
embolization: An audit of 84 patients. Hepatology 1999;29:
1099–1105.
8. Ikeda Y, Kajiyama K, Adachi E, et al.: Early recurrence after
surgery of hepatocellular carcinoma. Hepatogastroenterology
1995;42:469–472.
9. Nagao T, Inoue S, Yoshimi F, et al.: Postoperative recurrence of
hepatocellular carcinoma. Ann Surg 1990;211:28–33.
10. Shirabe K, Kanematsu T, Matsumata T, et al.: Factors linked to
early recurrence of small hepatocellular carcinoma after hepa-
tectomy: Univariate and multivariate analyses. Hepatology 1991;
14:802–805.
11. Poon RT, Fan ST, Ng IO, et al.: Different risk factors and
prognosis for early and late intrahepatic recurrence after resection
of hepatocellular carcinoma. Cancer 2000;89:500–507.
12. Tarao K, Rino Y, Takemiya S, et al.: Close association between
high serum ALT and more rapid recurrence of hepatocellular
carcinoma in hepatectomized patients with HCV-associated liver
cirrhosis and hepatocellular carcinoma. Intervirology 2000;43:
20–26.
13. Llovet JM, Bustamante J, Castells A, et al.: Natural history of
untreated nonsurgical hepatocellular carcinoma: Rationale for the
design and evaluation of therapeutic trials. Hepatology 1999;
29:62–67.
14. Pugh RN, Murray-Lyon IM, Dawson JL, et al.: Transection of the
oesophagus for bleeding oesophageal varices. Br J Surg 1973;60:
646–649.
15. Edmondson HA, Steiner PE. Primary carcinoma of the liver: A
study of 100 cases among 48,900 necropsies. Cancer 1954;7:
462–503.
16. Hermanek P, Henson DE, Hutter RVP et al. (eds): ‘‘TNM Sup-
plement 1993: A commentary on uniform use.’’ New York:
Springer-Verlag, 1993.
17. Ishak K, Baptista A, Bianchi L, et al.: Histological grading and
staging of chronic hepatitis. J Hepatol 1995;22:696–699.
18. Belghiti J, Regimbeau JM, Kianmanesh AR, et al.: Resection of
hepatocellular carcinoma: A European experience on 328 cases.
Hepatogastroenterology 2002;49:41–46.
19. Bilimoria MM, Lauwers GY, Doherty DA, et al.: Underlying
liver disease, not tumor factors, predicts long-term survival
after resection of hepatocellular carcinoma. Arch Surg 2001;136:
528–535.
20. Kosuge T, Makuuchi M, Takayama T, et al.: Long-term results
after resection of hepatocellular carcinoma: Experience of 480
cases. Hepatogastroenterology 1993;40:328–332.
21. Belghiti J, Panis Y, Farges O, et al.: Intrahepatic recurrence after
resection of hepatocellular carcinoma complicating cirrhosis. Ann
Surg 1991;214:114–117.
22. Ko S, Nakajima Y, Kanehiro H, et al.: Significant influence of
accompanying chronic hepatitis status on recurrence of hepato-
cellular carcinoma after hepatectomy. Result of multivariate ana-
lysis. Ann Surg 1996;224:591–595.
23. Jwo SC, Chiu JH, Chau GY, et al.: Risk factors linked to tumor
recurrence of human hepatocellular carcinoma after hepatic
resection. Hepatology 1992;16:1367–1371.
24. Bismuth H, Chiche L, Adam R, et al.: Liver resection versus
transplantation for hepatocellular carcinoma in cirrhotic patients.
Ann Surg 1993;218:145–151.
25. Mazzaferro V, Regalia E, Doci R, et al.: Liver transplantation for
the treatment of small hepatocellular carcinomas in patients with
cirrhosis. N Engl J Med 1996;334:693–699.
26. Yoshida Y, Kanematsu T, Matsumata T, et al.: Surgical margin and
recurrence after resection of hepatocellular carcinoma in patients
with cirrhosis. Further evaluation of limited hepatic resection.
Ann Surg 1989;209:297–301.
27. Lai EC, You KT, Ng IO, et al.: The pathological basis of resection
margin for hepatocellular carcinoma. World J Surg 1993;17:786–
790.
28. Nonami T, Harada A, Kurokawa T, et al.: Hepatic resection for
hepatocellular carcinoma. Am J Surg 1997;173:288–291.
29. Lise M, Bacchetti S, Da Pian P, et al.: Prognostic factors affecting
long term outcome after liver resection for hepatocellular
carcinoma: Results in a series of 100 Italian patients. Cancer
1998;82:1028–1036.
30. Poon RT, Fan ST, Ng IO, et al.: Significance of resection margin in
hepatectomy for hepatocellular carcinoma: Critical reappraisal.
Ann Surg 2000;231:544–551.
31. Adachi E, Maeda T, Kajiyama K, et al.: Factors correlated with
portal venous invasion by hepatocellular carcinoma: Univariate
and multivariate analyses of 232 resected cases without pre-
operative treatments. Cancer 1996;77:2022–2031.
32. Fuster J, Garcia-Valdecasas JC, Grande L, et al.: Hepatocel-
lular carcinoma and cirrhosis. Results of surgical treatment in a
European series. Ann Surg 1996;223:297–302.
33. Marsh JW, Dvorchik I, Bonham CA, et al.: Is the pathologic TNM
staging system for patients with hepatoma predictive of outcome?
Cancer 2000;88:538–543.
34. Suehiro T, Matsumata T, Itasaka H, et al.: Clinicopathologic
features and prognosis of resected hepatocellular carcinomas of
varied sizes with special reference to proliferating cell nuclear
antigen. Cancer 1995;76:399–405.
35. Kitamoto M, Nakanishi T, Kira S, et al.: The assessment of
proliferating cell nuclear antigen immunohistochemical staining
in small hepatocellular carcinoma and its relationship to histo-
logic characteristics and prognosis. Cancer 1993;72:1859–1865.
36. Soini Y, Virkajarvi N, Lehto VP, et al.: Hepatocellular carcinomas
with a high proliferation index and a low degree of apoptosis and
necrosis are associated with a shortened survival. Br J Cancer
1996;73:1025–1030.
37. Simonetti RG, Liberati A, Angiolini C, et al.: Treatment of
hepatocellular carcinoma: A systematic review of randomized
controlled trials. Ann Oncol 1997;8:117–136.
38. Raynard B, Mathurin P, Kirzin S, et al.: Me´ta-analyse des essais
controˆle´s des traitements adjuvants chez les patients ope´re´s d’un
carcinome he´patocellulaire. Gastroenterol Clin Biol 2001;25: A25.
39. Lau WY, Leung TW, Ho SK, et al.: Adjuvant intra-arterial iodine-
131-labelled Lipiodol for resectable hepatocellular carcinoma: A
prospective randomised trial. Lancet 1999;353:797–801.
40. Takayama T, Sekine T, Makuuchi M, et al.: Adoptive immu-
notherapy to lower postsurgical recurrence rates of hepatocellular
carcinoma: A randomised trial. Lancet 2000;356:802–807.
Risk for Early Death After Resection for HCC 41
